You have visited the Greek website of GENESIS Pharma. To learn more about our activity in Central and Eastern Europe, please visit

genesis slider

In 1997 we saw the future of treatment coming closer...

GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe
GENESIS Pharma SA started its activity in pharmaceutical biotechnology in 1997, at a time when biopharmaceutical industry was still at an early development stage in Europe. The company's goal was to combine the rapid progress in science with a successful and innovative business venture, thus paving the way for the creation of a new market. Working with consistency and dedication to this end, GENESIS Pharma SA became the first Greek pharmaceutical company specializing in the commercialization of innovative biopharmaceutical products. Today, the company is the largest among Greek companies specializing in innovative medicines, based on turnover.
In 1999, business activities were expanded in Cyprus through the creation of Genesis Pharma (Cyprus) Ltd, and later on, in markets of Southeast Europe. GENESIS Pharma (Cyprus) Ltd, an affiliate (sister) company, now operates in Central and Eastern Europe, through its subsidiaries in Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia, Slovenia (EU) as well as North Macedonia and Serbia (Non-EU). (
GENESIS Pharma has established long-term alliances with leading global biopharma companies and is responsible for a unique portfolio which includes innovative biopharmaceuticals that tackle severe and rare diseases. Its novel branded pharmaceutical products cover the therapeutic areas of Haematology, Oncology, Central Nervous System, Nephrology, Gastroenterology, Rheumatology, Dermatology as well as Rare Genetic Inherited diseases.